Glioblastoma (GBM) remains one of the least treatable types of cancer. Recent work highlights two key factors contributing to this resistant phenotype-cellular plasticity, the ability of GBM cells to adopt many phenotypes, and the microenvironment.
and therefore represents a promising target for combination with conventional chemotherapy in order to limit GBM recurrence.
INTRODUCTION
Glioblastoma (GBM) is the most aggressive and prevalent primary brain tumor in adults, with 10,000 new diagnoses each year. Recurrent tumors, with increased invasive and resistance capacities, are an inevitability for GBM patients despite aggressive therapeutic intervention. Glioma-initiating cells (GICs) are considered a key driver of primary tumor development, as well as major contributors to tumor recurrence [1] .
Recent reports demonstrate that differentiated GBM cells undergo cellular and molecular changes to acquire GIC-like states [2, 3] . This cellular plasticity dramatically complicates our ability to prevent tumor recurrence in the clinical setting. Our group and others have shown that therapeutic stress and microenvironmental dynamics induce cellular plasticity in GBM, driving the conversion of differentiated GBM cells to the GIC states [3] [4] [5] . However, the exact mechanisms governing post-therapy GBM plasticity remain unknown. Unraveling the signaling pathways that drive this plasticity will provide key insight for improving treatment of GBM.
Using gene expression and bioinformatics analysis, we identified Interleukin-8 (IL-8) as a key player in promoting post-therapy cellular plasticity. IL-8 enhances the selfrenewal capacity of patient-derived xenograft (PDX) GBM cells and is elevated in recurrent GBM patient specimens. Reducing levels of IL-8 in murine models significantly improved survival and enhanced the efficacy of Temozolomide chemotherapy. We demonstrate that IL-8/CXCR2 signaling alters the epigenomic landscape in GBM cells, inducing a GIC-like state and increasing the proportion of GICs after treatment. This study indicates that IL-8 signaling influences GBM plasticity and recurrence, highlighting it as a potential novel therapeutic target in GBM.
Materials and Methods

6
Cell Culture: U251 human glioma cell lines were procured from the American Type Culture Collection (Manassas, VA, USA). These cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; HyClone, Thermo Fisher Scienftific; San Jose, CA, USA) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA) and 1% penicillin-streptomycin (P/S) antibiotic mixture (Cellgro; Herdon, VA, USA; Mediatech, Herdon, VA, USA). Patient-derived xenograft (PDX) glioma specimens (GBM43, GBM12, GBM6, GBM5, and GBM39) were obtained from Dr. C. David James at Northwestern University and maintained according to published protocols [6] .
Animals:
Athymic nude mice (nu/nu; Charles River; Skokie, IL, USA) were housed according to all Institutional Animal Care and Use Committee (IACUC) guidelines and in compliance with all applicable federal and state statutes governing the use of animals for biomedical research. Briefly, animals were housed in shoebox cages with no more than 5 mice per cage in a temperature and humidity-controlled room. Food and water were available ad libitum. A strict 12-hour light-dark cycle was maintained.
Co-immunoprecipitation
For co-immunoprecipitation (Co-IP) experiments, proteins were extracted and quantified as described above. Then, 50-100µg of protein were incubated with primary antibody overnight at 4°C with gentle rocking. The next day, anti-rabbit IgG antibodies conjugated to agarose beads were added to the cell lysates and incubated for at least 1 hour at 22°C. Next, the mixture was spun down and washed several times in PBS. Finally, proteins were eluted from the mixture and loaded into gels, as described above.
Human Sample Histology:
Human primary and matched recurrent GBM tissue were obtained from the Northwestern University's Nervous System Tumor Bank. All patients were consented according to Institutional Review Board (IRB) policies prior to the obtainment of samples.
Samples were formalin-fixed and paraffin-embedded (FFPE). Immunohistochemistry of tumor samples was performed on 4-μm-thick sections heated at 60 °C for at least 1 hour.
Staining for IL-8 was carried out manually and antigen retrieval was performed with a Biocare Medical Decloaking Chamber using high (LC3) or low pH antigen retrieval buffer from Dako. Primary antibodies were incubated for 1 h at room temperature. A secondary antibody was EnVision labeled polymer-HRP (horseradish peroxidase) anti-mouse or antirabbit as appropriate. Staining was visualized using 3, 3′-diaminobenzidine (DAB) chromogen (Dako, K8000).
IL-8 immunohistochemical results on TMAs were semiquantified on a relative scale from 0 to 3, with 0 = negative and 3 = strongest (see Supplemental Figure 1 ). Each tumor was represented by 3 separate cores on 3 separate blocks.
Statistical analysis:
All statistical analyses were performed using the GraphPad Prism Software v4.0 (GraphPad Software, San Diego, CA, USA). Where applicable, one-way ANOVA, unpaired t-test, and log-rank test were applied. Survival distributions were estimated with the Kaplan-Meier method. A P value <0.05 was considered statistically significant.
For detailed methods and material please see the Supplementary Methods section.
Results:
Therapeutic stress increases IL-8 expression in vitro and in vivo 8
To investigate if Temozolomide (TMZ) chemotherapy promotes the adoption of a GIC state via cellular plasticity, gene set enrichment analysis (GSEA) using the Affymetrix platform and genome-wide ChIP-Seq analysis were performed. Data from patient-derived xenograft (PDX) GBM43 cells 4 and 8 days post-treatment with either vehicle control (DMSO) or physiological doses of TMZ (50μM) [7] [8] [9] revealed a significant (FDR q = 0.08, FWER p-value = 0.046) enrichment of a network of genes responsible for supporting the GIC phenotype ( Figure 1A ) [10] . In order to identify potential novel regulators of this process, we examined a variety of other genes for enhanced expression following TMZ.
Interestingly, gene expression revealed that Interleukin-8 (IL-8) is significantly upregulated post-TMZ therapy ( Supplementary Table 1 ). A recent report has demonstrated that epigenetic plasticity is a major driver of adaptation to targeted therapies in GBM8. To investigate the epigenetic regulation of plasticity during TMZ therapy, we next performed genome-wide ChIP-Seq analysis of TMZ-treated PDX GBM43 cells for histone 3 lysine Figure 1C ) (***P < 0.0001). To investigate if this increase translates to higher protein levels and is maintained in vivo, immunofluorescence analysis was performed on a previously established orthotropic recurrent GBM model2 and confirmed that recurrent tumors had increased IL-8 expression ( Figure 1E ). In light of the ability of therapy to induce both IL-8 expression and a GIC state, we next examined if alterations in cell state can influence such expression without therapy. Freshly isolated PDX lines were cultured in GIC maintenance media (neurobasal media supplement with appropriate growth factors) or differentiation condition media (1% fetal bovine serum) with or without TMZ (50μM). Even without any chemotherapy, culturing GBM PDX lines in the GIC maintenance media significantly elevated the expression of IL-8 expression measured by enzyme-linked immunosorbent assay (ELISA, Fig 1C) (****P < 0.0001). Proneural subtype GBM43 and the classical subtype GBM6 expressed about 20 and 200 folds higher IL8, respectively, in the GIC maintenance media as compared to differentiation condition media. TMZ exposure induced IL8 expression in both culture conditions (****P < 0.0001). Moreover, this induction was specific to TMZ, as another anti-glioma alkylating agent BCNU failed to promote IL8 expression in any GBM lines tested (***P < 0.001 and ****P < 0.0001, Supplementary Fig. S1 ). Based on this observation, we set out to investigate the role of IL-8 in promoting therapy-induced cellular plasticity and disease recurrence. Critically, we utilized differentiation condition media (1% FBS or Neural Basal Media with BMP2), as these conditions initiate differentiation of GBM cells and enable us to observe how stimuli induce dedifferentiation to the GIC state during therapy [5, 11] . Culturing cells in a GIC-promoting media (Neurobasal supplemented with growth factors like EGF and FGF) would be inappropriate for this study, as it would force the cells to a GIC state and mask any GIC-inducing effects of our experimental manipulations.
In silico analysis establishes IL-8 importance in GBM progression and patient outcomes
In order to examine the contribution of IL-8 to GBM clinical progression, we employed the Cancer Genome Atlas (TCGA) patient gene expression dataset. Our analysis illustrates that IL-8 transcript expression is elevated in World Health Organization (WHO) Grade IV glioma (GBM) (Figure 2A Next, to investigate IL-8 expression patterns across different tumor compartments, we utilized the Ivy Glioblastoma Atlas Project (IVY GAP) [12] , which demonstrated that IL-8 mRNA is elevated in pseudopalsading cells and the perinecrotic zone, two areas linked to the GIC subpopulation ( Figure 2F ). All of these data further justify our interest in IL-8 as a critical participant in GBM progression and therapy-induced plasticity.
Immunohistochemical analysis of IL-8 expression in matched primary recurrent GBM tissue
To investigate IL-8 expression in GBM tissue from patient samples, 75 GBM specimens from Northwestern University's Brain Tumor Bank were subjected to immunohistochemical characterization. Pathological analyses found approximately 65% (49/75) of GBM samples were IL-8-positive. Further, 17 matched primary and recurrent GBM tumor pairs were examined for IL-8 expression. We found elevated IL-8 in 65% (11/17) of recurrent tumors ( Figure 3A , 3B, and 3C). Critically, IHC analysis revealed high IL-8 expression in the typically hypoxic pernecrotic zone, an anatomical compartment where niche for the GIC was reported to be maintained 11-14 ( Figure 2F ). Our analysis also revealed that both tumor cells and infiltrating macrophages express IL8 ( Figure 3D and E).
IL-8 receptor CXCR2 + GBM cells acquire CD133 expression during anti-glioma chemotherapy
Next, we set to investigate how IL-8 signaling influence GBM proliferation and signaling. CXC motif chemokine receptors 1 and 2 (CXCR1 and CXCR2) are the major receptors for IL-8 [13] . To investigate their role in IL-8 mediated signaling in GBM, we first interrogated TCGA data. We observed that expression of both these receptors was significantly elevated in GBM tumors compared to low grade gliomas ( Figure S2 -A).
Analysis of our ChIP-seq data showed post therapy (4 days following exposure to 50µM TMZ) accumulation of open chromatim mark at a known enhancer site [14] for CXCR2 ( Figure 4A Moreover, CXCR2 expression was also elevated in the CD133 + GIC population ( Figure   4C ). Time course FACS following TMZ treatment revealed that a CXCR2 + cell population exists prior to TMZ treatment; this population rapidly gains CD133 expression during treatment ( Figure 4D ). CXCR1 expression was not altered during therapy ( Figure 4B and 
IL-8 increases the self-renewing capacity of GBM cells and the expression of GIC markers
To determine if the IL-8-CXCR signaling axis promotes induction of the GIC state in GBM, we performed extreme limiting dilution assay (ELDA) on GBM6 and GBM43 PDX cells in neurosphere media containing IL-8 (50 ng/ml). IL-8 increased GIC frequency about 3.3-fold for GBM43 and 2.3-fold for GBM6 ( Figure 5A , P=0.001). We next examined how IL-8 alters the expression of known GIC promoting genes, using our proprietary GIC-specific reporter cell line [11] . IL-8 activation significantly increased reporter activity ( Figure 5B and Figure S3 -A for SOX2-RFP reporter and Nanog-RFP reporter P = 0.0005). Next, to investigate how IL-8-CXCR signaling cascade interacts with the network of GIC-promoting genes in patient tumors, we selected the top GIC-associated genes activated during TMZ therapy ( Figure 1A and Supplementary Table 2 ) and correlated with their levels with IL-8 mRNA using the GlioVis data portal 16-18. IL-8 expression was significantly correlated with critical GIC associated genes including KLF4, CD44, HIF1A, HIF2A, Myc and Twist expression ( Figure 5C ). To examine the IL-8 expression in different anatomical location and potential colocalization of these GICspecific genes with areas of high IL-8 transcript level, we employed the Ivy Glioblastoma Atlas project; we observed that these genes transcripts were correlated with the IL-8 expression in both the perinecrotic zone and pseudopalsading cells ( Figure 5C , heat map;
Ivy Glioblastoma Atlas Project. Available from http://glioblastoma.alleninstitute.org).
Immunoblot analysis of PDX lines exposed to IL-8 show time-dependent induction these genes ( Figure 5D ) as well as various critical GIC-associated transcription factor such as Cmyc, Nanog, Sox2, OCT4 (and Figure S3 
IL-8 enhances GBM growth and therapy resistance in vivo
To elucidate IL-8's role during in vivo GBM growth, U251 cells with stable IL-8 knockdown were established using short hairpin RNA (shRNA) technology. IL-8 secretion was effectively knocked down by two shRNA constructs ( Figure S4 Figure   5F ).
IL-8 signaling promotes epigenetic alterations in GBM
To identify potential mechanisms by which IL-8 influences growth and promotes therapy resistance, we analyzed correlations between IL-8 and 12042 other genes using TCGA patient data via Pearson correlation coefficients. Our analysis returned 68 genes with coefficients >0.5 or <-0.5 and false discovery rate (FDR) <0.05 that correlate with IL-8; we then conducted unsupervised hierarchical clustering. Observed cophenetic correlation determined optimal clusters, which we validated by silhouette plots and principal component analysis (PCA). Two clusters with the highest cophenetic coefficient at 0.95 and average silhouette width at 0.46 ( Figure S5 and Figure 6A ) separated well upon visualization of PCA. Using the Enrichr platform, we determined that the first of these clusters (Group A) is involved in regulating cell chemotaxis (GO: 0060326, Adjusted Pvalue 1.058e-11) and cytokine activity (GO: 0005125, Adjusted P-value 2.495e-9), wellestablished canonical roles for IL-8 [15] . Cluster B includes genes enriched for wounding (GO: 009611, Adjusted P-value 0.002) and hypoxia (GO: 0001666, Adjusted P-value 0.004), also known IL-8 connections [16, 17] . Interestingly, IL-8 signaling also positively correlated with genes known to regulate epigenetic processes, specifically histone3 lysine27 trimethylation (H3K27me3) (GO: 0001666, Adjusted P-value 0.03).
Trimethylation of H3K27 suppresses gene expression via recruitment of the
Polycomb repressor complex (PRC), predominately regulated by two methyltransferases, EZH2 and G9a [18, 19] . Confirming our in silico result, treatment with IL-8 significantly increased trimethylation of H3K27, as well as another PRC complex target, H3K9 [20] , in three PDX lines ( Figure 6B ). Moreover, reduction of IL-8 expression via shRNA abolished methylation of the H3K27 and H3K9 residues ( Figure 6C) , with dose-dependent effects (Supplementary Figure S6-B ). IL-8 signaling alters histone status in GBM cells.
To further elucidate the connection between IL-8 and PRC, we next examined the status of crucial PCR members following IL-8 exposure. Phosphorylation of EZH2 in response to various extracellular stimuli remodels the epigenomic landscape, allowing cellular adaptation [21] . Specifically, phosphorylation at Thr345 enhances recognition of target genes leading to recruitment of PRC2 and suppression of transcription via H3K27me3 [22] . Contrastingly, extracellular signaling like AKT suppresses the methyltransferase activity of Ezh2 by phosphorylating Ser21 [23] . Our previous results illustrated that IL-8-CXCR interaction could activate various downstream signaling cascades, including PI3K-AKT ( Figure S6 -C & D) [24] . We, therefore, examined the alteration of the phosphorylation status of Ezh2 by IL-8 via immunoprecipitation (IP) in the nuclear and cytoplasmic fraction ( Figure 6D ). IL-8 stimulation enhanced phosphorylation of Ezh2 at both Ser21 and Thr345, exclusively in the cytoplasmic fraction.
However, within two hours of IL-8 stimulation, S21-phosphorylated (inhibited) EZH2 levels were decreased in the nucleus, while Thr345-phosphorylated (activated) Ezh2 accumulated. Binding of EZH2 to SUZ12, an essential PRC protein, increased only in the cytoplasmic compartment after IL-8 exposure, while the nuclear accumulation of Ezh2-SUZ12 complex gradually decreased. We conclude that within two hours of IL-8 exposure, the PRC2 activity may increase, but by 24 hours nuclear accumulation of PRC2 complex is reduced by heightened phosphorylation of EZH2 at Ser21.
To determine the functional effect of IL-8 on EZH2 activity, we analyzed two genes positively regulated by Ezh2 (OLIG2, SERPINB2) and two negatively regulated genes IL6R and BMP2K via qRT-PCR ( Figure 6E Given that TZM induces IL-8 signaling and Ezh2-dependent changes in histone status, we next examined the relationship between TMZ, IL-8, and Ezh-2 target histones.
We treated IL-8-knockdown cells with TMZ for 96 hours and analyzed histone status.
Reduced IL-8 levels abolished methylation of Ezh2 targets H3K27 and H3K9; however, H3K27ac decrease was minimal. Consequently, we suspect that chemotherapy-induced IL-8 signaling participates in for Ezh2-dependent epigenetic modifications during therapeutic stress. Finally, to investigate the role Ezh2/PRC2 complex activity in promoting therapyinduced cellular plasticity the GBM43 PDX line was treated with TMZ in the presence of 3-Deazaneplanocin A (DZNep, EZH2-I), a histone methyltransferase Ezh2 inhibitor. As shown in Figure 6H , DZNep completely abolishes the induction of a GIC population after therapy, as measured by FACS analysis of the CD133+ and CD15+ populations ( Figure   6H , P>0.0005).
Discussion:
The ability of GBM cells to adapt to current therapies and generate treatment-resistant recurrences represents one of the critical challenges facing brain tumor researchers and clinicians. Here, we provide data that sheds new light on mechanisms that may underlie this powerful ability to react to and overcome standard of care therapies. This study highlights the IL-8/CXCR2 signaling pathway as a critical player in this process and a potential target for blocking GBM cellular plasticity during therapy. Specifically, our data Induction of cellular plasticity, primarily when it promotes the adoption of therapy by inducing a GIC phenotype, is a well-established player in the formation of GBM recurrence. Indeed, several other groups and we have demonstrated how standard therapies can initiate this process and enrich GBM tumors with GIC cells [4, 5, 11, 27] . The ability to block this cellular plasticity remains a critical goal of contemporary research into novel therapies for GBM. However, targetable players in this process have yet to be identified.
Here, we provide some convincing evidence that IL-8 represents one such target. Our results show that IL-8 is sufficient to induce the GIC state on its own. Further, we show that it is both adequate and necessary for the adoption of GIC state during therapeutic stress.
These results indicate that IL-8 signaling is a potent regulator of GBM phenotype. Not only was IL-8 able to induce the expression of CD133 and CD15, two GIC phenotypic markers, it also caused increased expression of many transcription factors known to promote the GIC phenotype and recurrence, including HIF, c-myc, Sox-2, and CD44. In light of the ongoing debate regarding the precise gene expression profile of GICs, this robust induction, combined with our matched patient data, provides strong evidence that IL-8 is capable of activating cell reprogramming towards a more GIC-like state during anti-glioma chemotherapy.
Another key aspect of this study concerns the tumor microenvironment and how anticancer therapeutic can influence its composition. As previously mentioned, environmental cues are key regulators of GBM plasticity and the generation of recurrent growth. Here, we show that GBM cells actively sculpt their microenvironment following treatment with chemotherapy. This fact further corroborates a growing body of evidence that tumor cells actively cultivate a pro-growth microenvironment. An interesting facet of our data is the fact that culturing GBM cells in pro-GIC conditions alone led to an increase in IL-8 levels, Our data indicate for the first time that IL-8 is capable of causing alterations in the epigenetic status of key gene regulation factors, such as H3K27. While evidence increasingly shows the importance of epigenetic regulation in GBM growth and therapy resistance8, the mechanisms activating these processes remain incompletely understood.
Our work indicates that IL-8 represents one tumor-derived trigger for activating epigenetic responses to tumor therapy via modulation of the canonical PRC2 complex.
In sum, our data show that IL-8 is a key microenvironmental factor involved in promoting cellular plasticity in GBM. Through analysis of murine models and patient data, we illustrate the high degree of influence IL-8 holds over tumor progression. Further, our work Heatmap illustrates most significantly and differential expressed genes with a false discovery rate <0.01. mRNA expression in each anatomical compartment were compared. Cells were treated with either TMZ (50μM) or equimolar DMSO for four days prior to tumors, we selected the top GIC-associated genes activated during TMZ therapy ( Fig. 1A and Supplementary Table 2 ) and correlated with their levels with IL-8 mRNA using the Ivy Glioblastoma Atlas Project. Available from (http://glioblastoma.alleninstitute.org) data portal 16-18. IL-8 expression was significantly correlated with critical GIC associated genes including KLF4, CD44, HIF1A, HIF2A, Myc and Twist expression (Fig. 5C ). The Survival curves were obtained by the Kaplan-Meier method, and overall survival time was compared between groups using log-rank test. All statistical tests were two-sided. Bottom graph, to examine the role of IL-8 in GBM progression in a more clinically relevant manner, next the same method was used to knock down the IL-8 expression in GBM43 PDX line. 1.5X105 cells were injected stereotactically injected into the right hemisphere of the brain of athymic nude mice (n=8 per group, four male and four female). Survival curves were obtained by the Kaplan-Meier method, and overall survival time was compared between groups using log-rank test.
Representative immunoblot of different histone marks. A panel of PDX lines from a different subtype of GBMs was exposed to IL-8 (50ng/ml) for 24 hours. Nuclei were extracted from the harvested cells and subjected to immunoblot analysis for suppressive histone marks H3K27 and H3K9 trimethylation (me3) and activating mark H3K27 acetylation(ac). Immunoblotting for total histone three was performed to confirm the equal loading. C) The extracted nuclei from the U251 IL-8 knockdown cells as described in Figure 5F were subjected to immunoblot analysis for various histone marks as described above. D) GBM43 cells were treated with IL-8 (50ng/ml) for 2 and 24 hours, cytoplasmic and nuclear extract was prepared, cells were harvested, and immunoprecipitation assays were performed with the anti-EZH2 antibody. Immunoprecipitated protein was subjected to immunoblot analysis with antibodies against phosphor-EZH2 S21 and Thr345 and Nuclei were extracted from the harvested cells and subjected to immunoblot analysis for suppressive histone marks H3K27me3 and H3K9me2 and activating mark H3K27ac and H3K4me3. Immunoblotting for total histone three was performed to confirm equal loading.
G) The U251 IL-8 control and knockdown cells as described in figure 5A were treated with TMZ(50µM) for four days. Nuclei were extracted from the harvested cells and subjected to immunoblot analysis for suppressive histone marks H3K27me3 and H3K9me2 and activating mark H3K27ac. Left, representative densitometry analysis is expressed as
